Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
    • Conflicts of Interest Policy
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

November 20, 2025j3ff1

RespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License Agreement

November 19, 2025j3ff1

RespireRx Pharmaceuticals Inc. Announces Commencement of Rule 506(c) Private Placement 

November 18, 2025j3ff1
All News

NEWS: RespireRx Announces Department of Defense Award to Fund Phase 2 Clinical Study for its Lead AMPAkine

Read

NEWS: RespireRx Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

Read

©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.